BioNxt Solutions Announces Revocation of Management Cease Trade Order
BioNxt Solutions (OTC:BNXTF) announced that the British Columbia Securities Commission has revoked the temporary management cease trade order (MCTO) that was previously issued on May 1, 2025. The revocation comes after the company successfully filed its required annual financial documents for the year ended December 31, 2024.
The completion of these filings means that company management can now resume trading BioNxt securities. All annual filings are now accessible through the company's SEDAR+ profile.
BioNxt Solutions (OTC:BNXTF) ha annunciato che la British Columbia Securities Commission ha revocato l'ordine temporaneo di sospensione del commercio per la gestione (MCTO) precedentemente emesso il 1° maggio 2025. La revoca è avvenuta dopo che la società ha presentato con successo i documenti finanziari annuali richiesti per l'anno conclusosi il 31 dicembre 2024.
Il completamento di queste presentazioni consente ora alla direzione aziendale di riprendere la negoziazione dei titoli BioNxt. Tutti i documenti annuali sono ora accessibili tramite il profilo SEDAR+ della società.
BioNxt Solutions (OTC:BNXTF) anunció que la Comisión de Valores de Columbia Británica ha revocado la orden temporal de suspensión de comercio por gestión (MCTO) que se emitió anteriormente el 1 de mayo de 2025. La revocación se produce después de que la compañía presentara con éxito los documentos financieros anuales requeridos para el año finalizado el 31 de diciembre de 2024.
La finalización de estas presentaciones permite que la gerencia de la empresa reanude la negociación de los valores de BioNxt. Todos los documentos anuales están ahora disponibles a través del perfil SEDAR+ de la compañía.
BioNxt Solutions (OTC:BNXTF)는 브리티시컬럼비아 증권위원회가 2025년 5월 1일에 발행한 임시 경영 거래 정지 명령(MCTO)을 철회했다고 발표했습니다. 이 철회는 회사가 2024년 12월 31일 종료된 연도에 대한 필수 연간 재무 서류를 성공적으로 제출한 후 이루어졌습니다.
이 서류 제출 완료로 인해 회사 경영진은 이제 BioNxt 증권 거래를 재개할 수 있습니다. 모든 연간 서류는 회사의 SEDAR+ 프로필을 통해 확인할 수 있습니다.
BioNxt Solutions (OTC:BNXTF) a annoncé que la Commission des valeurs mobilières de la Colombie-Britannique a révoqué l'ordre temporaire de suspension des transactions de gestion (MCTO) précédemment émis le 1er mai 2025. Cette révocation intervient après que la société a déposé avec succès ses documents financiers annuels requis pour l'exercice clos le 31 décembre 2024.
La finalisation de ces dépôts permet désormais à la direction de reprendre la négociation des titres BioNxt. Tous les documents annuels sont désormais accessibles via le profil SEDAR+ de la société.
BioNxt Solutions (OTC:BNXTF) gab bekannt, dass die British Columbia Securities Commission die zuvor am 1. Mai 2025 erlassene vorübergehende Handelssperre für das Management (MCTO) aufgehoben hat. Die Aufhebung erfolgt, nachdem das Unternehmen seine erforderlichen Jahresfinanzdokumente für das am 31. Dezember 2024 endende Jahr erfolgreich eingereicht hat.
Mit dem Abschluss dieser Einreichungen kann die Unternehmensleitung den Handel mit BioNxt-Wertpapieren nun wieder aufnehmen. Alle Jahresunterlagen sind jetzt über das SEDAR+-Profil des Unternehmens zugänglich.
- Management cease trade order (MCTO) has been revoked
- Company has successfully completed and filed all required annual financial documents
- Company had previously failed to file annual documents on time, requiring an MCTO
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), is pleased to announce that effective immediately, the British Columbia Securities Commission has revoked the temporary management cease trade order ("MCTO") it had previously granted to the Company on May 1, 2025 under National Policy 12-203 Management Cease Trade Orders, as the Company successfully completed the filing of its annual audited financial statements, management's discussion and analysis, and related certifications for the year ended December 31, 2024 (collectively, the "Annual Filings") on June 26, 2025.
The revocation of the MCTO means members of management are no longer prevented from trading the Company's securities. All of the Annual Filings are available under the Company's profile on SEDAR+ at www.sedarplus.ca.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward‐Looking" Information
This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking information in this news release includes the anticipated filing date of the Annual Filings. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
What is the status of BioNxt Solutions' (BNXTF) management cease trade order?
Why was BioNxt Solutions (BNXTF) under a management cease trade order?
When did BioNxt Solutions (BNXTF) file its annual financial statements for 2024?
Where can investors access BioNxt Solutions' (BNXTF) annual financial filings?
